CA2234847A1 - Formulation for respiratory tract administration - Google Patents

Formulation for respiratory tract administration

Info

Publication number
CA2234847A1
CA2234847A1 CA002234847A CA2234847A CA2234847A1 CA 2234847 A1 CA2234847 A1 CA 2234847A1 CA 002234847 A CA002234847 A CA 002234847A CA 2234847 A CA2234847 A CA 2234847A CA 2234847 A1 CA2234847 A1 CA 2234847A1
Authority
CA
Canada
Prior art keywords
analgesic
formulation
respiratory tract
tramadol
tract administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002234847A
Other languages
French (fr)
Other versions
CA2234847C (en
Inventor
Mark Alfonso
Paul Goldenheim
Richard Sackler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Euro Celtique SA
Original Assignee
Mark Alfonso
Paul Goldenheim
Richard Sackler
Euroceltique, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mark Alfonso, Paul Goldenheim, Richard Sackler, Euroceltique, S.A. filed Critical Mark Alfonso
Publication of CA2234847A1 publication Critical patent/CA2234847A1/en
Application granted granted Critical
Publication of CA2234847C publication Critical patent/CA2234847C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A dosage form for intranasal and/or inhalation administration of an analgesic having low opioid receptor binding activity to a warm blooded animal, that includes a pharmaceutically effective amount of the analgesic. A preferred analgesic is tramadol, a tramadol and/or a pharmaceutically acceptable salt, metabolite or derivative thereof. Methods of making and using the formulation according to the invention are also provided.
CA002234847A 1995-11-14 1996-11-14 Formulation for respiratory tract administration Expired - Fee Related CA2234847C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/557,279 1995-11-14
US08/557,279 US6017963A (en) 1995-11-14 1995-11-14 Formulation for intranasal administration
PCT/US1996/018904 WO1997017948A1 (en) 1995-11-14 1996-11-14 Formulation for respiratory tract administration

Publications (2)

Publication Number Publication Date
CA2234847A1 true CA2234847A1 (en) 1997-05-22
CA2234847C CA2234847C (en) 2002-06-25

Family

ID=24224765

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002234847A Expired - Fee Related CA2234847C (en) 1995-11-14 1996-11-14 Formulation for respiratory tract administration

Country Status (8)

Country Link
US (3) US6017963A (en)
EP (1) EP0877609B1 (en)
JP (1) JP3152437B2 (en)
AT (1) ATE247461T1 (en)
AU (1) AU714303B2 (en)
CA (1) CA2234847C (en)
DE (1) DE69629591T2 (en)
WO (1) WO1997017948A1 (en)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
ATE251447T1 (en) * 1998-12-11 2003-10-15 Pharmachemie Bv PHARMACEUTICAL PREPARATIONS FOR INHALING AN OPIOID
US7640062B2 (en) 2000-05-08 2009-12-29 Brainsgate Ltd. Methods and systems for management of alzheimer's disease
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
JP4898073B2 (en) * 2000-07-31 2012-03-14 ニュコメデ ダンマルク アンパーツセルスカブ Fentanyl composition for intranasal administration
AU2001286518A1 (en) * 2000-08-15 2002-02-25 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
CA2424021A1 (en) * 2000-09-29 2002-04-04 Board Of Trustees Operating Michigan State University Catecholamine compositions and uses thereof
DE10049483A1 (en) * 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituted 1-aminobutan-3-ol derivatives
CA2435573A1 (en) * 2001-01-24 2002-08-01 Summamus Pharma Inc. Alkyl aryl polyether alcohol polymers for improvement of nasal breathing
US20040176359A1 (en) * 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
NZ528935A (en) * 2001-03-16 2004-10-29 Dmi Biosciences Inc Method of delaying ejaculation
WO2002094231A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of analgesics through an inhalation route
EP1392262A1 (en) 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US20030051728A1 (en) 2001-06-05 2003-03-20 Lloyd Peter M. Method and device for delivering a physiologically active compound
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
JP2005508888A (en) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション How to treat alcoholism or alcoholism
AU2002364517A1 (en) 2001-11-30 2003-06-17 Sepracor Inc. Tramadol analogs and uses thereof
IL164828A0 (en) * 2002-04-25 2005-12-18 Brainsgate Ltd Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
AU2003260367A1 (en) * 2002-08-06 2004-02-25 Glaxo Group Limited A dispenser
MXPA05001903A (en) * 2002-08-21 2005-04-28 Norton Healthcare Ltd Inhalation composition.
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
DE10248601B4 (en) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmaceutical agent for endonasal administration in the treatment of diseases and disorders of the central nervous system
JP2007516404A (en) 2003-05-21 2007-06-21 アレックザ ファーマシューティカルズ， インコーポレイテッド Optically or electrically ignited built-in heating unit and drug supply unit using the same
GB0400804D0 (en) 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
US8010189B2 (en) * 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US20060045849A1 (en) * 2004-08-24 2006-03-02 Farhan Taghizadeh Method of customizing the fragrance of nasal medications
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
US8758816B2 (en) * 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) * 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
DK2486942T3 (en) 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
JP2009504767A (en) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ Vitamin B12 nasal spray and method of use
CN101325944B (en) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 Compositions for nasal delivery
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
CA2640451C (en) * 2006-01-27 2011-09-13 Asahi Kasei Pharma Corporation Medicine for transnasal administration
US20080319083A1 (en) * 2006-01-27 2008-12-25 Asahi Kasei Pharma Corporation Medicine for transnasal administration
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
EP2486921A1 (en) 2007-02-12 2012-08-15 DMI Biosciences, Inc. Reducing Side Effects of Tramadol
BRPI0807282A2 (en) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Early Ejaculation Treatment and Co-morbid Erectile Dysfunction
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
WO2008147807A2 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
WO2009108867A1 (en) 2008-02-27 2009-09-03 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
KR20140145948A (en) * 2011-04-05 2014-12-24 옵토솔브 엘엘피 Ophthalmic treatments
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2668945A1 (en) * 2012-06-01 2013-12-04 Bayer Technology Services GmbH Genotype and phenotype-based medicinal formulations
CN104208044A (en) * 2013-05-29 2014-12-17 天津金耀集团有限公司 Tramadol hydrochloride inhalation preparation
ES2604816B1 (en) 2015-09-09 2018-01-29 Farmalider, S.A. Pharmaceutical composition of tramadol for ophthalmic use
IL272220B1 (en) 2017-08-20 2024-01-01 Formulex Pharma Innovations Ltd Dry powder compositions for intranasal delivery
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
RU2667808C1 (en) * 2017-12-19 2018-09-24 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" Method of acoustic-emission diagnostics of critical parts of freight-car trucks at operation
RU2697159C1 (en) * 2018-06-18 2019-08-12 Общество с ограниченной ответственностью "МЕЖДУНАРОДНЫЙ ЦЕНТР МОНИТОРИНГА НА ОСНОВЕ ВОЛНОВЫХ ПРОЦЕССОВ" Method of monitoring the technical condition of wheels of mobile composition during movement

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4440777A (en) * 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4624965A (en) * 1984-11-15 1986-11-25 Nastech Pharmaceutical Co., Inc. Novel method of administering anti-nausea and anti-emetic pharmaceutical agents and novel dosage forms containing same
US4749700A (en) * 1984-10-23 1988-06-07 Nastech Pharmaceutical Co, Inc. Novel methods of administering antihistamines, antinausea and antiemetic pharmaceutical agents and novel dosage forms containing same
EP0189861A3 (en) * 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
US4729997A (en) * 1985-10-15 1988-03-08 Nastech Pharmaceutical Co., Inc. Novel method of administering meclizine type pharmaceutical agents and novel dosage forms containing same
US5066648A (en) * 1985-11-29 1991-11-19 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
DE3602370A1 (en) * 1986-01-27 1987-08-06 Chrubasik Sigrun Use of analgesics by inhalation
US4778810A (en) * 1987-01-08 1988-10-18 Nastech Pharmaceutical Co., Inc. Nasal delivery of caffeine
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4973596A (en) * 1988-05-20 1990-11-27 Barr Laboratories, Inc. Method of administering a narcotic analgesic and dosage forms therefor
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
JP2875611B2 (en) * 1990-08-29 1999-03-31 エーザイ株式会社 Topical formulation containing calcium silicate
DE122004000032I2 (en) 1991-09-06 2006-02-09 Mcneilab Inc Composition containing a tramadol compound and acetaminophen, and their use
HU217584B (en) * 1991-09-06 2000-02-28 Mcneilab Inc. Pharmaceutical compositions containing at least one of the following compounds tramadole,- derivative and codeine, oxycodone or hydrocodone and process for producing them
US5223541A (en) * 1991-09-13 1993-06-29 Mcneilab, Inc. Tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
ATE188119T1 (en) 1992-02-07 2000-01-15 Kaken Pharma Co Ltd REMEDIES FOR WOUNDS AND HEMORRHOIDS
DE4221256C2 (en) * 1992-06-26 1997-07-10 Lancaster Group Ag Galenic composition for topical use
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
WO1994004139A1 (en) 1992-08-21 1994-03-03 Dana Farber Cancer Institute Treatment of human viral infections
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
JPH06199701A (en) * 1992-12-29 1994-07-19 Lion Corp Anti-inflammatory analgesic agent for external use
DE69432789T2 (en) * 1993-03-26 2003-12-04 Franciscus Wilhelmus H Merkus PHARMACEUTICAL COMPOSITIONS FOR THE INTRANASAL ADMINISTRATION OF APOMORPHINE
WO1994022459A1 (en) 1993-04-07 1994-10-13 Eisai Co., Ltd. Immunopotentiative and infection-protective agent, containing two or more bacillus, egg white and garlic
US5451408A (en) * 1994-03-23 1995-09-19 Liposome Pain Management, Ltd. Pain management with liposome-encapsulated analgesic drugs

Also Published As

Publication number Publication date
JP3152437B2 (en) 2001-04-03
US6642275B2 (en) 2003-11-04
DE69629591D1 (en) 2003-09-25
EP0877609B1 (en) 2003-08-20
CA2234847C (en) 2002-06-25
EP0877609A1 (en) 1998-11-18
AU714303B2 (en) 1999-12-23
JPH11500148A (en) 1999-01-06
US20010049391A1 (en) 2001-12-06
AU1060497A (en) 1997-06-05
WO1997017948A1 (en) 1997-05-22
EP0877609A4 (en) 2000-06-07
US6017963A (en) 2000-01-25
US20020022663A1 (en) 2002-02-21
ATE247461T1 (en) 2003-09-15
DE69629591T2 (en) 2004-07-01

Similar Documents

Publication Publication Date Title
CA2234847A1 (en) Formulation for respiratory tract administration
CA2024916A1 (en) Respiratory disorder medicaments comprising salmeterol and fluticasone propionate
CA2389235A1 (en) Controlled release hydrocodone formulations
CA2374877A1 (en) Pharmaceutical formulations and methods comprising intranasal morphine
MY125662A (en) Pharmaceutical formulations containing darifenacin
EP1468679A3 (en) Controlled release formulation containing tramadol
CA2360248A1 (en) Combinations of formoterol and a tiotropium salt
HUP0004383A2 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
CA2226934A1 (en) Ipratropium bromide enantiomer with a prolonged duration of action
ATE361077T1 (en) INDANYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES
WO2004037222A3 (en) Sustained-release tramadol formulations with 24-hour efficacy
ATE204160T1 (en) FORMULATION FOR INHALATION APPLICATION
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
CA2370501A1 (en) Pharmaceutical composition for the therapy of lower urinary tract symptoms
WO2002030955A3 (en) Tetrapeptide stimulating functional activity of hepatocytes and its therapeutical use
CA2340920A1 (en) A method for preventing the onset of asthma
AU7285696A (en) Administration by inhalation of 2-amino-6n-propylamino-4,5,6,7-tetrahydrobenzothiazol, in particular of its (-)enantiomer and its pharmacologically tolerable acid addition salts
WO2005087192A3 (en) Salmeterol inhalation formulations
MY111155A (en) Medicaments
TH16088A (en) Inhalation formulation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20121114